This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New hypothesis paper builds on a growing scientific consensus that Parkinson's disease route to the brain starts in either the nose or the gut and proposes that environmental toxicants are the likely source.
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
FRIDAY, April 12, 2024 -- A chlamydia vaccine has triggered immune responses in an early trial, raising hopes that one day it might help curb the spread of the sexually transmitted infection (STI).There is currently no vaccine for chlamydia, which.
Only biopharma could have combated Covid-19; no other industry has the capacity to do so. When the world was in crisis, this industry responded. If need be, it will again, despite the financial consequences.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Star Trek's Holodeck is no longer just science fiction. Using AI, engineers have created a tool that can generate 3D environments, prompted by everyday language.
The first medicine approved for PPD, Sage’s Zulresso, never gained traction. The company is in the midst of launching its second, but long-standing challenges could slow uptake.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
The first medicine approved for PPD, Sage’s Zulresso, never gained traction. The company is in the midst of launching its second, but long-standing challenges could slow uptake.
MONDAY, April 8, 2024 -- New research questions the effectiveness of the U.S. Food and Drug Administration's accelerated drug approval program after finding that many cancer drugs remain unproven five years later.The study, published Sunday in the.
Nils Pemberton, Nina Compagne, Argyrides Argyrou, Emma Evertsson, Anders Gunnarsson, Jason G. Kettle, Jonathan P. Orme, and Richard A. Ward ACS Medicinal Chemistry Letters 2024 DOI: 10.1021/acsmedchemlett.3c00425 To further facilitate the discovery of cysteine reactive covalent inhibitors, there is a need to develop new reactive groups beyond the traditional acrylamide-type warheads.
Researchers have discovered a simple, but effective, strategy to help people reduce their feelings of anger. Disposing of a piece of paper containing your written thoughts on the cause of your anger can effectively neutralize it. This process is like a Japanese tradition called hakidashisara, in which people write their negative thoughts on a plate then destroy it.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
FRIDAY, April 12, 2024 -- More than 100 measles cases have already been reported in the United States this year, a significant increase over previous years that threatens the country's attempts to eliminate the illness, federal health officials.
Lavleen K. Mader and Jeffrey W. Keillor ACS Medicinal Chemistry Letters 2024 DOI: 10.1021/acsmedchemlett.4c00054 Experiments comprising a “pre-incubation” phase, where enzyme is incubated with inhibitor prior to the addition of assay substrate, are commonly used to evaluate covalent inhibitors, often via discontinuous or “endpoint” IC50 assays. However, due to the lack of mathematical tools to describe its biphasic time-dependent nature, this experiment has thus far been unable to provide kinact
In a new breakthrough that could revolutionise medical and material engineering, scientists have developed a first-of-its-kind molecular device that controls the release of multiple small molecules using force.
The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
THURSDAY, April 11, 2024 -- Kentucky resident Chasity Harney embraced a thoroughly healthy lifestyle -- eating right, exercising and never touching tobacco.So, her 2018 diagnosis of advanced lung cancer, which came at the age of 40, was a complete.
Struck-by injuries are the leading cause of nonfatal injuries and second most common cause of fatalities among construction workers. From 2011 to 2022, there were 1,462 fatal occupational injuries that occurred at road construction sites.[1] Of these, 68% (n=1,000) were among workers in the construction industry (See figure) followed by workers in transportation and warehousing (11%; n=168) and professional and business services (9%; n=132) industries.
Findings show a newly created drug can prevent runaway inflammation while still allowing the immune system to handle the virus, even when given late into infection.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
THURSDAY, April 11, 2024 -- The discovery of a gene variant that rids the brain of toxic plaques linked to Alzheimer's might lead to new treatments for the disease, researchers report.The variant arises naturally in people who don't seem to get.
#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. KIF1A-Related Research Genetic Alterations in a Large Population of Italian Patients Affected by Neurodevelopmental Disorders We often talk about genetic disorders in the context of mutations that change a protein̵
TUESDAY, April 9, 2024 -- For people struggling with both diabetes and a common type of heart failure, the weight-loss drug Wegovy may do more for their health than help them shed pounds, new research suggests.In the study, published Saturday in.
Documentation is a crucial part of your analytics implementation. From your Solution Design Reference document to your internal wiki for all resources, making sure that you can write and edit your documentation is key to ensuring a cohesive and thorough understanding of your implementation. With effective documentation, you can: Prevent knowledge gaps among team members and assist in onboarding efforts.
The full power of next-generation quantum computing could soon be harnessed by millions of individuals and companies, thanks to a breakthrough guaranteeing security and privacy. This advance promises to unlock the transformative potential of cloud-based quantum computing.
MONDAY, April 8, 2024 -- A pancreatic cancer vaccine has continued to protect a small group of patients from their cancer coming back, three years after receiving the jab, a new study says.Eight patients have not had their pancreatic cancer recur.
Delivery of ribonucleoprotein (RNP) into cells is an essential factor for successful CRISPR gene editing. However, this is difficult to guarantee using traditional CRISPR gene editing methods, especially in hard-to-transfect cells. The standard CRISPR technique involves gathering a group of cells and then electroporating them, using short high-voltage pulses to overcome the barrier of their cell membranes.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content